Navigate Fool.com
Will PLX beat
the market?
Community Rating: 2 Stars: Unattractive

4.18 -0.13 (-3.02%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.40
Previous Close $4.31
Daily Range $4.12 - $4.40
52-Week Range $3.70 - $5.81
Market Cap $391.2M
P/E Ratio 14.37
Dividend (Yield) $0.00 (0.0%)
Volume 215,512
Average Daily Volume 197,727
Current FY EPS -$0.08

How do you think PLX
will perform against the market?

Top PLX Bull/Bear Pitches


yellowear (< 20)
Submitted December 20, 2008

Based on the news on the street and the performance of the stock at these levels, this company has the potential of reaching 2000% in the next 4 years. This stock has found a bottom like AKS did seve … More

1 Replies Reply Report this Post

cashsage (< 20)
Submitted April 22, 2009

PLX has a too high valuation compared to its sales potential. Its current sales are nil, and so is one of the most loss making companies.

0 Replies Reply Report this Post

News & Commentary

3 High-Risk, High-Reward Biotech Stocks for Long Term Investors

Everyone wants to get rich, but investing in the wrong developmental companies can have disastrous consequences. Here are three companies with game-changing potential that have yet to hit their stride -- and may payoff in the long run.

Sector Update: Healthcare Shares Edging Higher in Pre-Bell Trade

Sector Update: Healthcare

Oppenheimer Sees Five Biotech Stocks to Buy With Potential 50% Upside, or More

The Simplest Biotech Growth Portfolio Ever

Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.

Is This Orphan Drugmaker in Trouble?

Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?

Can Protalix Revolutionize This Orphan Disease?

The latest results in Protalix's pipeline may be from a phase 1 trial, but don't let that fool you. If successful, PRX-112 could run laps around Shire and Sanofi and catch the attention of larger partners, including Pfizer.

Should You Buy Protalix for Its Platform Alone?

Does disruptive potential trump poor finances for this developmental-stage company?

How Far Can $69 Million Take Protalix?

A debt offering sent shares south. How far can the extra cash take this biotech?

5 of Last Week's Biggest Losers

These five stocks posted double-digit declines this past week.

See More PLX News...





Protalix BioTherapeutics, Inc. (PLX) Description

A clinical stage biopharmaceutical company that is focused on developing and manufacturing recombinant therapeutic proteins that are produced through its proprietary plant cell system. Website: http://www.protalix.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks